Molecular Biology of Kidney Cancer
Fig. 3.1 Control of HIF activity. Steady-state levels of HIFα are controlled by its rate of synthesis and degradation. The former is regulated by the TORC1 complex, which contains the…
Presurgical Therapy in Renal Cell Carcinoma
Group N Study type Treatment Primary tumor Disease state MD Anderson Cancer Center [9] 50 Prospective Bevacizumab+/– erlotinib Resectable Metastatic with primary in place: 50 University of North Carolina [6]…
Combinatorial and Sequential Targeted Therapy in Metastatic Renal Cell Carcinoma
Combinations Author, pub date # of patients Outcomes Combinations of targeted agents Bevacizumab and everolimus Hainesworth, 2010 [6] 80 Median PFS 9.1 months in untreated patients, 7.1 months patients previously…
Angiogenesis Inhibitor Therapy in Renal Cell Cancer
Fig. 17.1 RCC biology which leads to VEGF upregulation. Therapeutics are listed in the red boxes that target major elements of this pathway 17.3 Inhibition of VEGF in Renal Carcinoma…
Adjuvant Systemic Therapy for Renal Cell Carcinoma
T-stage N M Year T1 T2 T3 T4 1987 [8] ≤2.5 cm >2.5 cm T3a: perinephric or adrenal extension T3b: renal vein involvement T3c: vena cava below diaphragm Beyond…
The Role of Radiation Therapy in Renal Cell Carcinoma
Author, year Treatment Number of patients 5-year survival Significant difference Van der Werf-Messing et al. 1981 [12] RT + N 89 50 % No N 85 Juusela et al. 1977…
Epidemiology of Renal Cell Carcinoma
Established risk factors Risk factors that need further study Cigarette smoking Dietary factors: Fruit and vegetables Alcohol Obesity Reproductive factors and other hormones: Oral contraceptive pills Parity Hypertension Occupational exposures:…
Biomarkers for Renal Cell Carcinoma
Fig 4.1 Biomarker-relevant biologic pathways in renal cell carcinoma (RCC). In VHL-/- tumor cells, the absence of pVHL results in the accumulation of hypoxia-inducible factor alpha (HIF-α). HIF accumulation could…
Genetic Heterogeneity of Kidney Cancer
© Springer International Publishing 2015Primo N. Lara and Eric Jonasch (eds.)Kidney Cancer10.1007/978-3-319-17903-2_5 5. Genetic Heterogeneity of Kidney Cancer David Sun1 , Eric Jonasch3 and Primo N. LaraJr.2 (1) Deapartment of Internal Medicine, Division of Hematology-Oncology, University of California Davis Comprehensive…
Rapid Review of Breast Cancer Treatment Side Effects and Dietary Supplement/Integrative Options from A to Z: What Helps, Harms, or Does Nothing?
(1) Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA (2) Jenkins/Pokempner Director of Complementary & Alternative Medicine, University of Michigan Medical Center (Dept of Urology), Ann…
